Guard argues new data render primary endpoint miss 'irrelevant,' tripling share price

Guard Therapeutics is mounting a bullish bounce back from the failure of its phase 2 kidney injury clinical trial. A primary endpoint failure brought the study to an early end, but the Swedish biotech branded that setback “irrelevant” Tuesday, arguing that longer-term efficacy assessments show its asset has a future.